Background: Extended liver resections are being performed more liberally than ever. The extent of resection of liver metastases, however, is restricted by the volume of the future liver remnant (FLR). An intervention that would both accomplish tumor control and induce compensatory hypertrophy, with good patient tolerability, could improve clinical outcomes.
Case Presentation: A 53-year-old woman with a history of cervical cancer presented with a large liver mass. Subsequent biopsy indicated poorly differentiated carcinoma with necrosis suggestive of squamous cell origin. A decision was made to proceed with pre-operative chemotherapy and Y-90 microsphere SIRT with the intent to obtain systemic control over the disease, downsize the hepatic lesion, and improve the FLR. A surgical exploration was performed six months after the first SIRT (three months after the second). There was no extrahepatic disease. The tumor was found to be significantly decreased in size with central and peripheral scarring. The left lobe was satisfactorily hypertrophied. A formal right hepatic lobectomy was performed with macroscopic negative margins.
Conclusion: Selective internal radiation treatment (SIRT) with yttrium-90 (Y-90) microspheres has emerged as an effective liver-directed therapy with a favorable therapeutic ratio. We present this case report to suggest that the portal vein radiation dose can be substantially increased with the intent of inducing portal/periportal fibrosis. Such a therapeutic manipulation in lobar Y-90 microsphere treatment could accomplish the end points of PVE with avoidance of the concern regarding tumor progression.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2655298 | PMC |
http://dx.doi.org/10.1186/1477-7819-7-6 | DOI Listing |
Eur J Nucl Med Mol Imaging
December 2024
Ankara University Medical School Department of Nuclear Medicine, Ankara, Turkey.
Purpose: The aim of this study was to investigate the relationship between voxel-based dosimetric variables derived from Y-90 PET/MRI and hypertrophy observed in the left lobe after radioembolization and to investigate if there is any difference in hypertrophy induced by glass versus resin microspheres.
Methods: Voxel-based dosimetry-derived variables and their relationship with the change of the standardized future liver remnant (ΔFLR) was investigated with linear regression models. To compare and evaluate the discriminatory power of the dosimetric variables, ROC analyses were utilized.
Chest
October 2024
Department of Medicine, King Faisal Specialist Hospital and Research Centre, Madinah, Saudi Arabia. Electronic address:
Ann Nucl Med
August 2024
Department of Nuclear Medicine, Ankara University Medical School, Ankara, Turkey.
Purpose: In this study, we aimed to evaluate the response of the primary and metastatic liver tumors to radioembolization with Y glass microspheres and investigate its correlations with dosimetric variables calculated with Y PET/MRI.
Methods: In this ambispective study, 44 patients treated with Y glass microspheres and imaged with Y PET/MRI were included for analysis. Dosimetric analysis was performed for every perfused lesion using dose-volume histograms.
Front Oncol
August 2024
School of Medicine, Washington University in St. Louis, St. Louis, MO, United States.
Background: Radioembolization with yttrium-90 (Y-90) is utilized to treat primary liver malignancies. The efficacy of this intra-arterial therapy in arterially hypoperfused tumors is not known.
Methods: We reviewed data of patients with primary liver tumors treated with Y-90 prescription doses of at least 150 Gy.
Oncologist
August 2024
Department of Radiology, University of Washington, Seattle, WA, United States.
Background: Evaluating transarterial radioembolization (TARE) in patients with metastatic colorectal carcinoma of the liver who have progressed on first-line chemotherapy (EPOCH) demonstrated superior outcomes using yttrium-90 glass microspheres plus chemotherapy (TARE/Chemo) vs chemotherapy (Chemo) to treat colorectal liver metastases. Additional exploratory analyses were undertaken to assess the impact of TARE/Chemo on efficacy, safety, time to subsequent therapy, time to deterioration in quality of life (QoL), and identify criteria for improved patient selection.
Methods: Time to deterioration in QoL was analyzed for the primary study population.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!